MedTrace Logo

Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy

NCT00663949 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2008-04-22

No results posted yet for this study

Summary

Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they can not hinder the progression of renal disease completely. Pentoxifylline as a TNFa blocker may hinder progression of diabetic nephropathy in combination of captopril.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Captopril

25 mg captopril tablet q8h

DRUG

Captopril + Pentoxifylline

patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Jamshid Roozbeh, MD · sums

  • mohammad ghezloo, MD · SUMS

  • mohammad mahdi sagheb, MD · SUMS

  • Amin Banihashemi · SUMS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-12-31
Completion
2008-01-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663949 on ClinicalTrials.gov